13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

BEAT Stock Analysis & AI Quality Score

AI stock analysis and institutional research for HeartBeam, Inc. (BEAT), a Healthcare sector company. BEAT is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), HeartBeam, Inc. reports net income of $-4.7M, free cash flow of $-3.9M. Top institutional holders of BEAT by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, BlackRock,, GEODE CAPITAL MANAGEMENT,, based on the most recent SEC filings. BEAT trades on the Nasdaq exchange and files with the SEC under CIK 1779372. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BEAT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for HeartBeam, Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-4.7M

Free Cash Flow

Q1 2026

$-3.9M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Net Income

-32.9% YoY
$-19.4MFY 2024
FY21 $-4.4MFY22 $-13.0MFY23 $-14.6MFY24 $-19.4M

Operating Income

-29.9% YoY
$-19.9MFY 2024
FY21 $-2.3MFY22 $-13.0MFY23 $-15.3MFY24 $-19.9M

EPS (Diluted)

-1.4% YoY
$-0.73FY 2024
FY21 $-1.03FY22 $-1.59FY23 $-0.72FY24 $-0.73

Total Assets

-80.9% YoY
$3.3MFY 2024
FY21 $14.0MFY22 $4.0MFY23 $17.1MFY24 $3.3M

Op. Cash Flow

-19.7% YoY
$-14.5MFY 2024
FY21 $-3.2MFY22 $-9.9MFY23 $-12.1MFY24 $-14.5M

AI Insight: BEAT Financial Trends

HeartBeam remains unprofitable with consistent $5M quarterly net losses and minimal equity cushion eroding to $1M by Q1 2026.

Operating cash burn stabilized at $3–4M per quarter since Q2 2025, improving from $4M in Q4 2024.

Equity declined 89% from $9M (Q2 2024) to $1M (Q1 2026), raising solvency concerns.

Equity at $1M in Q1 2026 — company approaching insolvency; further losses threaten going concern.

No revenue visible across eight quarters — product commercialization or financing critical within months.

AI Insight: BEAT Ratio Trends

Insufficient data to assess HeartBeam's financial trends — all ratio metrics are missing across all periods.

No operating margin, net profit margin, ROE, ROA, ROIC, or debt-to-equity figures available for analysis.

Data collection or reporting gap prevents evaluation of profitability, efficiency, and leverage trends.

Get alerted when BEAT's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for HeartBeam, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)
XBRL financial facts (revenue, EPS, margins)
Insider transactions (Form 4)
Institutional 13F holdings
Quality rankings (32 signals)
AI analyst debates & daily meetings
Historical financial trends
Peer comparison & sector analysis

Top Institutional Holders of BEAT

Put BEAT on your watchlist

Track score changes the day HeartBeam, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Is BEAT a good stock to buy?

13F Pro's AI-powered analysis of HeartBeam, Inc. (BEAT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for BEAT are available on the BEAT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own BEAT?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling BEAT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of HeartBeam, Inc.'s investment landscape.